Claritin Extension Should Be Debated As Product-Specific Bill - Barr CEO
The merits of a patent extension for Schering-Plough's Claritin should be debated in the context of a specific bill for that purpose, Barr CEO Bruce Downey contended at a House Judiciary/Courts & Intellectual Property Subcommittee hearing May 21.
You may also be interested in...
FDA revisited Claritin animal carcinogenicity data and its relevance to humans two and a half years into its review of the Schering-Plough antihistamine following an agency restructuring, the General Accounting Office said in an Aug. 10 report.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011